Minor Cannabinoids as an Emerging Frontier for Pain Relief.

Autor: Ippolito MJ; Department of Neural Sciences, Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania (M.J.I.); Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, California (E.R.G.); Department of Anesthesiology, Pharmacology and Therapeutics and Djavad Mowafaghian Center for Brain Health, University of British Columbia, Vancouver, British Columbia (K.S.A.-E.); Department of Medical Sciences, College of Medicine and Health Science, Khalifa University, Abu Dhabi, United Arab Emirates (K.S.A.-E.); and Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt (K.S.A.-E.)., Gross ER; Department of Neural Sciences, Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania (M.J.I.); Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, California (E.R.G.); Department of Anesthesiology, Pharmacology and Therapeutics and Djavad Mowafaghian Center for Brain Health, University of British Columbia, Vancouver, British Columbia (K.S.A.-E.); Department of Medical Sciences, College of Medicine and Health Science, Khalifa University, Abu Dhabi, United Arab Emirates (K.S.A.-E.); and Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt (K.S.A.-E.) ergross@stanford.edu., Abd-Elrahman KS; Department of Neural Sciences, Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania (M.J.I.); Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, California (E.R.G.); Department of Anesthesiology, Pharmacology and Therapeutics and Djavad Mowafaghian Center for Brain Health, University of British Columbia, Vancouver, British Columbia (K.S.A.-E.); Department of Medical Sciences, College of Medicine and Health Science, Khalifa University, Abu Dhabi, United Arab Emirates (K.S.A.-E.); and Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt (K.S.A.-E.).

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2024 Oct 18; Vol. 391 (2), pp. 132-134. Date of Electronic Publication: 2024 Oct 18.

A M1 muscarinic acetylcholine receptor-specific positive allosteric modulator VU0486846 reduces neurogliosis in female Alzheimer's mice.

Autor: Abd-Elrahman KS; Department of Anesthesiology, Pharmacology and Therapeutics, and Djavad Mowafaghian Centre for Brain Health, The University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada; Department of Medical Sciences, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt. Electronic address: khaled.abdelrahman@ubc.ca., Colson TL; University of Ottawa Brain and Mind Research Institute, Ottawa, Ontario K1H 8M5, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada., Sarasija S; University of Ottawa Brain and Mind Research Institute, Ottawa, Ontario K1H 8M5, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada., Ferguson SSG; University of Ottawa Brain and Mind Research Institute, Ottawa, Ontario K1H 8M5, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada; Department of Neuroscience, Faculty of Health Sciences, Carleton University, Ottawa, Ontario K1S 5B6, Canada. Electronic address: sferguso@uottawa.ca.

Publikováno v: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Apr; Vol. 173, pp. 116388. Date of Electronic Publication: 2024 Mar 09.

Targeting mGluR group III for the treatment of neurodegenerative diseases.

Autor: Rabeh N; Department of Physiology and Immunology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates; Department of Anesthesiology, Pharmacology and Therapeutics, and Djavad Mowafaghian Center for Brain Health, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada., Hajjar B; Department of Physiology and Immunology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates., Maraka JO; Department of Physiology and Immunology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates., Sammanasunathan AF; Department of Physiology and Immunology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates., Khan M; Department of Physiology and Immunology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates., Alkhaaldi SMI; Department of Physiology and Immunology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates., Mansour S; Department of Physiology and Immunology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates., Almheiri RT; Department of Physiology and Immunology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates., Hamdan H; Department of Physiology and Immunology, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi 127788, United Arab Emirates; Healthcare Engineering Innovation Center (HEIC), Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates., Abd-Elrahman KS; Department of Anesthesiology, Pharmacology and Therapeutics, and Djavad Mowafaghian Center for Brain Health, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada; Department of Pharmacology and Therapeutics, College of Medicine and Health Science, Khalifa University, Abu Dhabi 127788, United Arab Emirates; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt. Electronic address: khaled.abdelrahman@ubc.ca.

Publikováno v: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Dec; Vol. 168, pp. 115733. Date of Electronic Publication: 2023 Oct 18.

VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.

Autor: Ibrahim KS; University of Ottawa Brain and Mind Research Institute.; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada.; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt., El Mestikawy S; Neuroscience Paris Seine, Institut de Biologie Paris Seine, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Sorbonne Université, 75006, France Paris.; Department of Psychiatry, Douglas Hospital Research Center, McGill University, Montreal, Quebec H4H 1R3, Canada., Abd-Elrahman KS; University of Ottawa Brain and Mind Research Institute.; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada.; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt., Ferguson SSG; University of Ottawa Brain and Mind Research Institute sferguso@uottawa.ca.; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada.

Publikováno v: The Journal of neuroscience : the official journal of the Society for Neuroscience [J Neurosci] 2023 Jun 07; Vol. 43 (23), pp. 4365-4377. Date of Electronic Publication: 2023 Apr 13.

Adipose tissue mitochondrial dysfunction and cardiometabolic diseases: On the search for novel molecular targets.

Autor: AlZaim I; Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon; Department of Pharmacology and Toxicology, American University of Beirut, Beirut, Lebanon; Current Affiliation: Department of Biomedicine, Aarhus University, Høegh-Guldbergsgade 10, 8000 Aarhus C, Denmark., Eid AH; Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar., Abd-Elrahman KS; University of Ottawa Brain and Mind Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada; Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. Electronic address: kshabdel@ucalgary.ca., El-Yazbi AF; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; Faculty of Pharmacy, Alalamein International University, Alalamein, Egypt. Electronic address: Ahmed.fawzy.aly@alexu.edu.eg.

Publikováno v: Biochemical pharmacology [Biochem Pharmacol] 2022 Dec; Vol. 206, pp. 115337. Date of Electronic Publication: 2022 Nov 05.